what is biomarin developing as a cure
BioMarin Pharmaceutical develops enzyme therapies for serious, life-threatening diseases and conditions. We are committed to improving the lives of patients by developing novel enzyme therapies for currently unmet medical needs. BioMarin is currently sponsoring a clinical trial of enzyme replacement therapy for MPS IVA (Morquio A). A natural history study of MPS IVA, sponsored by BioMarin, is underway in the United States and several other countries. In May 2005, Naglazyme received marketing approval from the U.S. Food and Drug Administration (FDA) for the treatment of individuals with MPS VI.